WP
IMNM icon

Woodline Partners’s Immunome IMNM Stock Holding History

Woodline Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.2M Sell
1,000,398
-575,000
-36% -$12.3M 0.07% 356
2026
Q1 		$34.5M Hold
1,575,398
– – 0.13% 211
2025
Q4 		$33.8M Buy
1,575,398
+300,669
+24% +$5.28M 0.13% 202
2025
Q3 		$14.9M Sell
1,274,729
-383,934
-23% -$3.82M 0.07% 342
2025
Q2 		$15.4M Buy
1,658,663
+934
+0.1% +$7.66K 0.08% 342
2025
Q1 		$11.2M Buy
1,657,729
+676,804
+69% +$6.49M 0.07% 341
2024
Q4 		$10.4M Buy
980,925
+56,533
+6% +$683K 0.07% 333
2024
Q3 		$13.5M Buy
924,392
+1,500
+0.2% +$21.3K 0.11% 244
2024
Q2 		$11.2M Sell
922,892
-395,164
-30% -$6.18M 0.11% 237
2024
Q1 		$32.5M Buy
1,318,056
+395,164
+43% +$8.02M 0.3% 100
2023
Q4 		$9.87M Buy
+922,892
New +$7.67M 0.11% 230

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Woodline Partners's IMNM Position: Q2 2026 in Review

Woodline Partners reduced its Immunome (IMNM) stake by 36% in Q2 2026, selling an estimated $12.3M and leaving 1,000,398 shares worth $21.2M. The position accounts for 0.07% of the portfolio, ranked #356.

Woodline Partners first reported a position in IMNM in Q4 2023 and has held it in 11 quarters since. The position peaked at $34.5M in Q1 2026. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Woodline Partners held 1,000,398 shares of Immunome worth $21.2M as of Q2 2026.
  • Woodline Partners sold 575,000 Immunome shares in Q2 2026, an estimated $12.3M.
  • Immunome made up 0.07% of Woodline Partners's portfolio in Q2 2026, its #356 holding.
  • Woodline Partners first reported a position in Immunome in Q4 2023 and has held it in 11 quarters since.
  • Woodline Partners's Immunome position peaked at $34.5M in Q1 2026.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.